Gadobenate dimeglumine-enhanced magnetic resonance imaging of primary leiomyoma of the liver

Daniele Marin, Carlo Catalano, Massimo Rossi, Antonino Guerrisi, Michele Di Martino, Pasquale Berloco, Roberto Passariello

Research output: Contribution to journalArticlepeer-review


We report a case of histologically proven primary leiomyoma of the liver that was evaluated with multiphasic 64-section computed tomography (CT) and gadobenate dimeglumine-enhanced magnetic resonance (MR) imaging. This lesion showed vivid enhancement during the arterial phase with sustained enhancement during the hepatic venous and equilibrium phases. During the liver-specific MR imaging phase (150 minutes after contrast injection), the same lesion demonstrated lack of contrast retention, thus appearing hypointense compared with the background liver. Because of this latter finding, the patient underwent partial resection of the liver. In primary hepatic leiomyoma, the absence of contrast uptake during the liver-specific phase of gadobenate dimeglumine-enhanced MR imaging may be inappropriately interpreted as a sign of malignancy, thus leading to unnecessary, aggressive management of such lesions.

Original languageEnglish
Pages (from-to)755-758
Number of pages4
JournalJournal of Magnetic Resonance Imaging
Issue number3
Publication statusPublished - Sep 2008


  • Benign liver tumors
  • Liver, MR
  • Liver, MR contrast agents

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology


Dive into the research topics of 'Gadobenate dimeglumine-enhanced magnetic resonance imaging of primary leiomyoma of the liver'. Together they form a unique fingerprint.

Cite this